Profilo
Dr. Chris Wahl is a Chief Scientific Officer at Halozyme Therapeutics, Inc. Dr. Wahl was previously employed as a Vice President-Strategy & Business Development by Biora Therapeutics, Inc., a Chief Operating Officer by Interface Therapeutics, Inc., and a Chief Operating Officer by Micropharma Ltd. He received his undergraduate degree from Lee University, an MBA from McGill University and a doctorate degree from McGill University.
Posizioni attive di Chris Wahl
| Società | Posizione | Inizio |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Chris Wahl
| Società | Posizione | Fine |
|---|---|---|
| BIORA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Interface Therapeutics, Inc. | Fondatore | - |
Micropharma Ltd.
Micropharma Ltd. Pharmaceuticals: MajorHealth Technology Formulates, manufactures & sells functional food, neutraceuticals and pharmaceutical products | Direttore operativo | - |
Formazione di Chris Wahl
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Micropharma Ltd.
Micropharma Ltd. Pharmaceuticals: MajorHealth Technology Formulates, manufactures & sells functional food, neutraceuticals and pharmaceutical products | Health Technology |
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lee University
Lee University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biora Therapeutics, Inc.
Biora Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company focused on developing targeted therapies for cancer and autoimmune diseases | Health Technology |
Interface Therapeutics, Inc. |
















